机构名称：
¥ 3.0
A second session was held on 4 th January in which the same Clinical Executive Directors in addition to support from the Chief Operating Officer and Director of Strategy assessed the quality and safety impact (using ratings of High/ Medium/ Low) of not supporting investment for the following GMOs which require funding in 23/24 to deliver and rated as critical/ high priorities by the Service Group or Programme Board: Primary Care, Community and Therapies, Children and Young People, Maternity, Value Based Healthcare, Sustainability/脱碳和人口健康。临床执行董事的反应通常是一致的，并且彼此一致。在会议上同意，由于不支持投资，对患者的潜在影响，被评估为高质量和安全影响的转基因生物也被视为对卫生委员会的高声誉影响；这些
会议日期 - 斯旺西湾大学卫生委员会
主要关键词
相关文件推荐
